This includes CAR T cells directed against CD19 [for acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and chronic lymphocytic leukemia (CLL)]; CD22 (to treat ALL); and B cell maturation antigen (BCMA) to treat multiple myeloma. The gene discussed is CD22; the disease is non-Hodgkin lymphoma.